Founded in 2020, Immunocan Biotech Co., Ltd. is a biotechnology company dedicated to building antibody drug discovery platforms using innovative gene editing technology. Our goal is to empower global antibody drug R&D with proprietary gene-edited animal platform generating human and alpaca antibody, suitable for different drug discovery scenarios.
| Website | https://immunocan.com |
| Employees | 10 (7 on RocketReach) |
| Founded | 2020 |
| Address | 625 Massachusetts Ave, Cambridge, Massachusetts 02139, US |
| Industry | Biotechnology Research |
| Keywords | Gene Editing Technology, Biotechnology, Therapeutic Antibodies, Immunotherapy, Drug Development, Biopharmaceutical, Pharmaceutical Research, Precision Medicine, Cancer Treatment, Molecular Biology, Biotechnology Platform, Drug Discovery Platform, Protein Engineering, Cell Therapy, Oncology, Biologics, Pharmaceutical, Clinical Development |
| Competitors | Amgen, Genentech, AstraZeneca, Bristol Myers Squibb, Merck & Co., Inc., Pfizer, Roche, Johnson & Johnson, Novartis, Lilly India +40 more (view full list) |
Looking for a particular Immunocan employee's phone or email?
Yu Zhang is the Vice President of Business Development of Immunocan.
7 people are employed at Immunocan.
Immunocan is based in Cambridge, Massachusetts.